Please join us in Stockholm at the City Conference Centre (Folkets Hus), for three exciting days of presentations by invited speakers as well as poster presentations.

The major focus of the 2012 Stockholm meeting will be on new targets and drugs for the treatment of Alzheimer's disease. The World's leaders in the field will discuss new trial designs, animal models, neuroimaging including PET and diagnostic recommendations as well as CSF and blood markers. Emerging Novel Therapeutic Targets will be presented. We expect approximately 1500 participants, mostly neurologists, psychiatrists, geriatricians and pharmacologists.

The bi-annual International Stockholm / Springfield Symposium on Advances in Alzheimer Therapy distinguishes itself from other scientific meetings of this kind for two main characteristics.

First, is the only international meeting that focuses entirely on the pharmacological therapy of Alzheimer Disease with particular emphasis on the discovery of new drugs. The theme includes: drug development at different preclinical and clinical stages, results of clinical trials and pharmaco-economics implications.

Second, the meeting is organized by an American (Southern Illinois University, School of Medicine in Springfield Illinois, USA) and two European (University of Geneva, Medical School Dept. of Rehabilitation and Geriatrics, and Karolinska Institutet, Dept. of Neurobiology, Care Sciences and Society, Stockholm, Sweden) universities.

Our next meeting will take place in Stockholm at the City Conference Centre (Folkets Hus), May 9-12, 2012. It will be the 12th of the series. The last one was in Geneva in 2010.

We expect that the results of several new clinical trials, presently in progress in the whole world, will be communicated at the 2012 meeting. The meeting is also unique insofar as bringing together basic and clinical experts of this area from academia as well as from the most important pharmaceutical companies. We would like to underline the fact that several drugs presently used in the treatment of Alzheimer Disease were first presented at various Springfield meetings. The Springfield meeting which spans over 3 days, includes monothematic Symposia, communications on New Therapies and posters.

The conference will be useful to specialists, mainly neurologists, psychiatrists and geriatricians as well to any one caring for Alzheimer patients, in order to understand the pharmacological approach to the disease.

Course Directors
Ezio Giacobini, MD, PhD, Geneva
Gabriel Gold, MD, Geneva
Agneta Nordberg, MD, PhD, Stockholm